UBS Assumes Eli Lilly at Buy, Raises Price Target to $710
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh has assumed Eli Lilly (NYSE:LLY) with a Buy rating and raised the price target to $710.
October 20, 2023 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst has given Eli Lilly a Buy rating and raised the price target to $710, indicating a positive outlook for the company.
The Buy rating and increased price target from UBS analyst Trung Huynh suggest a positive outlook for Eli Lilly. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100